For Q4 2025, PacBio generated total revenue of 44645000, up year-over-year, with GAAP net loss of 40371000 and gross profit of 16566000. Non-GAAP gross margin improved to 40% compared to 31% in the prior year quarter.
Revenue increased to 44645000 from 39224000 year-over-year.
Consumables revenue reached 21600000, up from 18800000.
GAAP gross profit was 16566000 with 37% gross margin.
Revio placements were 21 and Vega placements were 42 during the quarter.
Management highlighted strengthened balance sheet following the sale of short-read assets and expects growth acceleration with the upcoming SPRQ-Nx launch aimed at lowering sequencing costs.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance